Obalon Therapeutics Inc (NASDAQ:OBLN) VP Matthew Norwood bought 1,000 shares of the company’s stock in a transaction on Wednesday, October 12th. The shares were acquired at an average price of $15.00 per share, with a total value of $15,000.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.
Shares of Obalon Therapeutics Inc (NASDAQ:OBLN) opened at 13.00 on Tuesday. Obalon Therapeutics Inc has a 12 month low of $12.33 and a 12 month high of $15.88. The firm’s 50 day moving average is $14.04 and its 200 day moving average is $14.04.
About Obalon Therapeutics
Obalon Therapeutics, Inc is a commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company’s product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients.
Receive News & Ratings for Obalon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obalon Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.